|
Crestor Cholesterol-lowering drug, also known as rosuvastatin, is a drug in a class of medications
called HMG-CoA reductase inhibitors or more commonly referred to as
statins. Crestor Cholesterol-lowering drug works to inhibit the production of an enzyme in the
liver that causes cholesterol.
A factor that distinguishes Crestor Cholesterol-lowering drug (rosuvastatin) from the other five
statins on the market is that Crestor’s potential to cause kidney
toxicity is far greater. AstraZeneca halted clinical trials after
reports of kidney damage and muscle weakness became known in patients
taking 80 milligrams of Crestor per day. (Muscle weakness is an early
symptom of rhabdomyolysis.) The FDA’s review noted that in contrast to
currently approved statins, rosuvastatin (Crestor) was also associated
with renal [kidney] findings not previously reported with other statins.
However, according to AstraZeneca’s documentation of Crestor – it tells
another story: Crestor Cholesterol-lowering drug is generally well tolerated. Adverse reactions
have usually been mild and transient. In clinical trials of 10,275
patients, the most commonly reported treatment-related adverse events
were myalgia, constipation, asthenia, abdominal pain, and nausea.
Crestor Cholesterol-lowering drug is contraindicated in patients with active liver disease or
unexplained persistent elevations of serum transaminases and in women
who are pregnant or may become pregnant, and in nursing mothers.
|
